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Introduction
Results and discussion





Vancomycin is a glycopeptide antibiotic, which can be sterilised by radiation treatment. In this study, the drug substance, as well as a controlled-release formulation 
drug product, were subjected to radiation receiving a Ph.Eur.-recommended sterilisation dose of 25 kGy and an overkill dose of 50 kGy. In addition, non-irradiated 
samples were also subjected to a 2 and 4 hours heat treatment, mimicking the radiation temperature effects. The treated samples, as well as untreated control samples, 
were quantitatively assayed with isocratic HPLC-UV and the results confirmed with LC-MS, FT-IR and TLC. 
Quantitative assay by HPLC-UV  
Confirmation and investigations with LC-MS, FT-IR ant TLC
Conclusions
A decreasing trend in HPLC-UV assay-values is observed after radio-sterilisation and some degradation product were detected with LC-MS. 
No massive degradation of vancomycin as drug substance nor as formulated drug product could be detected, even at the overkill dose of 
50kGy: the assay value in the samples treated with an overkill dose of 50kGy are at the under-limit of the quality specifications required by 
the Ph. Eur. monograph for the drug substance. Several radiation-originated degradation products were detected by LC-UV/MS, accounting 
for 5.6 % of the total related impurities of 7.5%, consistent with the assay loss determined by quantitative HPLC-UV.
Treatment Drug substance Drug product
25 kGy 94.5% 95.9%
50 kGy 92.5% 92.6%
2 hrs 50°C 96.5% 97.8%
4 hrs 50°C 98.1% 99.2%
A decreasing trend in assay-values is observed. When comparing these results 
with the Ph. Eur. quality specifications for the drug substance, only the samples 
treated with an overkill dose of 50kGy are at 93% under-limit.
Table 1. Mean assay results of vancomycin (versus untreated control)
1)  LC-MS

























Figure 2: IR spectra of 50kGy treated and untreated sample. 
Conditions: - KBr pellets
- Perkin-Elmer 2000 FT-IR
- Rs: 2 cm-1 / BG corrected. 
H
H
Forced degradations: 0.1M HCl, 0.5M NaOH and 30% H2O2 for 4 hours at 60°C. 
Forced degradations: 
- HCl: more than 50% DESV + some aglucovancomycin (not shown) 
- NaOH: massive dispersed degradation
- H2O2: no major degradation observed
Radiosterilised (overkill 50 kGy): degradation-peaks are observed:
Peak a (m/z = 1412): ±0.6%
Peak b (m/z = 1305): ±3.4 [also present in untreated samples at ±1.2%]
Peak c (m/z = 1463): ±0.8%
Peak d (m/z = 1428 and 1463): ±1.7% [m/z 1428 peak also present at 0.7% in untreated sample] 
Peak e (m/z = 1428): ±1.0% 
Figure 1: From top to bottom; UV chromatograms of untreated vancomycin(±1.25mg/mL), H2O2 treated 
(0.1mg/mL), HCl treated (0.1mg/mL), and 50kGy irradiated vancomycin(±2mg/mL). Mass spectra of 
vancomycin peak(v) (vancomycin) and desvancosaminylvancomycin (DESV) peak (b).
3)  TLC
Radiation conditions: - Mean electron energy on Ta: 10 MeV
- Resulting X electro-magnetic radiation energy: 1.5 MeV
- Irradiation time: 2 hours (25 kGy) and 4 hours  (50 kGy)                                
HPLC Conditions:      - Column: Lichrospher 100 RP 18 (5 µm; 4.0 x 250 mm) (21°C ± 5°C)
- Mobile phase: 1/7/92 %V THF/AcCN/0.4% TEA (pH 3.2 – H3PO4)       
- Flow: 1.2 mL/min
- UV detection:  λ = 280 nm
- Injection volume:  25 µL
- Samples: ± 125 µg/ml (Zn2+ treated)
Preliminary investigations: no massive degradation-peak found.
Final conditions (Diana et al, 2006) 
- Column:Zorbax extended C18 (5 µm; 3.0 x 250 mm) (21°C ± 5°C)
- Mobile phase: MeOH/H2O/0.2 M NH4OAc pH 9.0 (30/65/5 %V); flow: 0.15 µL
- UV detection:  λ = 285 nm
- Injection volume:  20 µL
- MS detection: LCQ iontrap (Thermo-Finnigan) in positive mode
Conditions: - Plate: Silicagel 60F254
- Mobile phase: H2O/1-Propanol (40/60 %V)
- Concentration: 0.5 mg/ml
- Spot: 20 µL 
- Detection: HClO4 20%, 10 min 120°C 
No significant changes in the IR spectra are observed, 
indicative that no major, functional degradant is formed.
No significant degradation spots could be observed for the 
irradiated samples on the plates. The HCl and NaOH forced 
degradation experiments samples clearly show major 
degradation spots.     
(Standard deviation: ± 2.5%)
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